MindWalk Holdings (HYFT) Consolidated Net Income (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Consolidated Net Income of $930.12 for Q2 2026, down 99.9% year-over-year from $895979.1 in Q2 2025, and up 29.8% quarter-over-quarter from $716.55 in Q4 2025.
Analysis
MindWalk Holdings (HYFT) Consolidated Net Income (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Consolidated Net Income for 7 consecutive years, with $930.12 the latest figure, recorded in Q2 2026.
- In Q2 2026, Consolidated Net Income fell 99.9% year-over-year to $930.12; the TTM figure through Apr 2026 stood at $821.7 million (up 421.75% YoY), while the FY2026 annual figure was $841120.4, down 59.78% from the prior year.
- Consolidated Net Income grew to $930.12 in Q2 2026 per HYFT's latest filing, from $716.55 in the prior quarter.
- Across five years, Consolidated Net Income topped out at $3.1 billion in Q3 2023 and bottomed at -$32.9 million in Q2 2023.
- Historically, Consolidated Net Income has averaged $313.9 million across 5 years, with a median of $727895.0 in 2024.
- Annual changes were most pronounced in 2022 — Consolidated Net Income plunged 328.73% — and 2023, when it jumped 1025793.57%.
- MindWalk Holdings' Consolidated Net Income stood at $3.9 million in 2022, then jumped by 32982.56% to $1.3 billion in 2023, then slumped by 99.94% to $727895.0 in 2024, then tumbled by 99.9% to $716.55 in 2025, then climbed by 29.8% to $930.12 in 2026.
- Business Quant data shows HYFT's Consolidated Net Income at $930.12 in Q2 2026, $716.55 in Q4 2025, and $821.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.70 Bn | 58.52 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.56 Bn | 52.42 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.16 Bn | 35.06 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.63 Bn | 32.32 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.63 Bn | 27.79 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.73 Bn | 26.57 Bn | 358.27 Mn | -13.27 Mn |
| 10 | MindWalk Holdings | 61.22 Mn | 52.95 Mn | 1.82 Mn | -2.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | -2.50 Mn |
| Jan 31, 2026 | -2.66 Mn |
| Oct 31, 2025 | -1.97 Mn |
| Jul 31, 2025 | 1.01 Mn |
| Apr 30, 2025 | -13.25 Mn |
| Jan 31, 2025 | -19.33 Mn |
| Oct 31, 2024 | -2.78 Mn |
| Jul 31, 2024 | 75,222.13 |
| Apr 30, 2024 | -17.56 Mn |
| Jan 31, 2024 | -3.05 Mn |
| Oct 31, 2023 | -2.21 Bn |
| Jul 31, 2023 | -3.03 Bn |
| Apr 30, 2023 | -5.82 Mn |
| Jan 31, 2023 | -3.32 Mn |
| Oct 31, 2022 | -5.53 Mn |
| Jul 31, 2022 | -7.52 Mn |
| Apr 30, 2022 | -4.19 Mn |
| Jan 31, 2022 | -3.57 Mn |
| Oct 31, 2021 | -3.88 Mn |
| Jul 31, 2021 | -2.97 Mn |